BeOne Medicines (NASDAQ:ONC) Director Margaret Dugan Sells 212 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Margaret Dugan sold 212 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total value of $65,635.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Down 0.8%

ONC stock opened at $300.01 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $235.57 and a 1-year high of $385.22. The firm has a market cap of $32.92 billion, a P/E ratio of 67.12 and a beta of 0.50. The business’s 50 day moving average is $301.85 and its 200-day moving average is $321.12. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ONC. Royal Bank Of Canada increased their price target on BeOne Medicines from $423.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Guggenheim increased their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley reissued an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and cut their price target for the company from $420.00 to $290.00 in a research note on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $389.15.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds have recently modified their holdings of ONC. Bank of America Corp DE bought a new position in shares of BeOne Medicines in the 2nd quarter valued at about $67,657,000. Man Group plc bought a new position in shares of BeOne Medicines in the 2nd quarter valued at about $59,031,000. Capital International Investors grew its holdings in shares of BeOne Medicines by 3.3% in the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock valued at $1,716,883,000 after acquiring an additional 161,052 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of BeOne Medicines in the 2nd quarter valued at about $38,337,000. Finally, First Trust Advisors LP grew its holdings in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.